The Beauty Health Company (SKIN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

The Beauty Health Company (SKIN) is anticipated to report its Q2 2025 earnings on August 7, with consensus estimates projecting a quarterly loss of $0.06 per share, a 40% year-over-year improvement, despite a 17.7% revenue decline to $74.55 million. Crucially, a positive Zacks Earnings ESP of +20.00% combined with a #2 Zacks Rank indicates a high probability that SKIN will beat consensus EPS estimates, positioning it as a compelling earnings-beat candidate that could see stock appreciation, though broader market factors will also influence post-release performance.

Analysis

The Beauty Health Company (SKIN) is positioned for a likely earnings per share (EPS) beat in its upcoming Q2 2025 report, though this is set against a backdrop of significant top-line pressure. Wall Street consensus anticipates a narrowed quarterly loss of $0.06 per share, a 40% improvement year-over-year, but projects a sharp 17.7% decline in revenue to $74.55 million. The primary bullish catalyst is the combination of a Zacks Rank #2 (Buy) and a strong positive Earnings ESP of +20.00%, a pairing that historically predicts an earnings beat with nearly 70% accuracy. This optimism is further supported by a 3.85% upward revision in the consensus EPS estimate over the past 30 days and a substantial +38.46% surprise in the prior quarter. Despite these positive indicators for an earnings surprise, the company's mixed history of beating estimates only twice in the last four quarters and the fundamental weakness implied by the revenue contraction present a conflicting picture. The market's reaction will therefore heavily depend on management's forward guidance and ability to address the revenue decline during the August 7 earnings call.

Key Decisions for Investors

• Given the strong quantitative indicators pointing to an EPS beat, such as the +20.00% Earnings ESP and #2 Zacks Rank, investors may consider establishing a tactical long position ahead of the earnings release to capture potential short-term upside from a positive surprise.
• Traders should remain cautious of the underlying business weakness indicated by the projected 17.7% year-over-year revenue decline, as a negative outlook or weak guidance from management could easily overshadow an EPS beat and pressure the stock.
• The most critical data point will be management's commentary on the earnings call; investors should listen closely for specific strategies to reverse the revenue downtrend, as this will determine the sustainability of any post-earnings stock movement.